Navigation Links
Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
Date:9/3/2014

CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMOTM, a Phase 2 study in patients with iNHL, and DUOTM, a Phase 3 study in patients with CLL.

Under the terms of the agreement, Infinity will receive an upfront payment of $275 million and is eligible to receive up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib. In the U.S., the companies will jointly commercialize duvelisib and will share equally in any potential profits. Outside the U.S., AbbVie will be responsible for the conduct and funding of commercialization of duvelisib, and Infinity is eligible to receive tiered double-digit royalties on net product sales.

"We believe that duvelisib is a very promising investigational treatment based on clinical data showing activity in a broad range of blood cancers," said Michael Severino, M.D., AbbVie executive vice president and chief scientific officer. "The addition of duvelisib will complement AbbVie's emerging oncology pipeline and expand our research into combination therapies
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transonic Systems Selects Infinity Info Systems To Implement Microsoft Dynamics CRM To Drive Business Performance And Operational Excellence
2. Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
3. Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood
4. Elektas Leksell Gamma Knife Perfexion and Elekta Infinity Place First and Second in 2013 KLAS Radiation Therapy Report
5. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
6. InfinityQS to Host Manufacturing Intelligence Conference in Chicago
7. AbbVie Named to S&P 500 Dividend Aristocrat Index
8. AbbVie Issues Inaugural Full-Year Outlook for 2013
9. AbbVie to Present at Barclays Global Health Care Conference
10. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
11. AbbVie to Host First-Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "China PTCA Balloon Market Investment Report, 2014-2016" ... balloon, as a indispensable medical device in percutaneous coronary ... for stent, but also as a device for pre-/post-stent ... closely related to that of PCI. As ...
(Date:9/18/2014)... 2014  Iliad Neurosciences, Inc., a company focused on ... Autism Spectrum Disorders (ASD) announced today that it has ... Foundation for The State University of New York. ... biomarker to identify an abnormality in folate transport to ... is expected to be available for research use by ...
(Date:9/18/2014)... Pa. , Sept. 18, 2014 /PRNewswire/ ... solutions, was recognized as the Disruptive Innovator ... its ePharmaONE cloud-based eClinical platform. This solution ... electronic trial master file (eTMF), a remote ... and ePharmaSolutions, ReferralPlus+ patient screening and matching ...
Breaking Medicine Technology:China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... 2011 UCB, a leading biopharmaceutical company at the forefront ... College of Gastroenterology (ACG) meeting in Washington, D.C. by reinforcing ... disease. At this year,s ACG meeting, a large body of ... in treatment of moderate to severe Crohn,s disease. ...
... Natrix Separations, Inc. announced today new members of its leadership ... Officer and Molly S. McGlaughlin as Vice President of Business ... of Directors since mid-2010, and will continue to hold a ... C. Howie Honeyman, Ph.D. will continue as Senior Vice ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 2UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 3Natrix Separations Introduces New Leadership Team 2Natrix Separations Introduces New Leadership Team 3
(Date:9/18/2014)... 2014 TayganPoint Consulting Group, a ... President and co-founder John Cassimatis was named as ... for 2014, recognizing the region’s top healthcare and ... executive of the year. , The Innovation Awards ... that continue to shape the medical industry in ...
(Date:9/18/2014)... microbes -- don,t worry, it,s a good thing! As ... microbes are bad. Many active enzymes and bacteria are ... as an important part of our digestive system or ... albicans , an opportunistic yeast pathogen and model organism ... healthy personal ecosystem. However, when our immune system is ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... York, New York (PRWEB) September 18, 2014 ... ) continue to mount in U.S. courts, Bernstein ... has recommended that the U.S. Food & Drug ... new restrictions that, if implemented, could greatly reduce ... Bone, Reproductive and Urologic Drug Advisory Committee, and ...
(Date:9/18/2014)... News) -- Teens and young adults who,ve been mentored ... provides them with greater responsibility and independence early on ... "We found that having a mentor provides a clear ... author, Steve McDonald, an associate professor of sociology at ... release. In conducting the study, published online ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4Health News: Mentors May Steer Young People Toward More Rewarding Careers 2
... approach to treatment that focuses on recovery from mental ... acclaim for the Medical College of Georgia Department of ... Project GREAT, or the Georgia Recovery-Based Educational Approach ... to be part of their own care, while also ...
... FRIDAY, Feb. 24 (HealthDay News) -- Sudden Infant Death Syndrome ... German researchers reports. DNA analysis from a small group ... the male children carried a particular enzyme mutation that may ... the case for female SIDS patients. Study author Dr. ...
... Overweight or obese people with chronic kidney disease may suffer ... new study warns. Cleveland Clinic researchers analyzed the eating ... who took part in the U.S. National Health and Nutrition ... percent said they had tried to lose weight in the ...
... Serena Gordon HealthDay Reporter , FRIDAY, Feb. 24 ... on their own take a companion -- usually a spouse ... office visits, researchers report. And they tend to bring ... health care system with another important member of a patient,s ...
... , This release is available in Spanish ... and the university hospital Virgen de las Nieves in Granada ... toxic than that traditionally used and only targets cancerous tissue. ... efficient cancer postoperative treatment for cases of cancer of the ...
... Cells that die naturally generate a lot of internal debris ... leading to diseases such as lupus., Now Georgia Health Sciences ... a woman,s immune system from attacking a fetus also helps ... such as DNA or joints. , The findings point ...
Cached Medicine News:Health News:Psychiatry program garners national education award 2Health News:Psychiatry program garners national education award 3Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 2Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 3Health News:Dieting Can Prove Dangerous for Kidney Disease Patients 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 3Health News:A new radiotherapy technique significantly reduces irradiation of healthy tissue 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: